A detailed history of Harbor Capital Advisors, Inc. transactions in Castle Biosciences Inc stock. As of the latest transaction made, Harbor Capital Advisors, Inc. holds 138,707 shares of CSTL stock, worth $3.86 Million. This represents 0.23% of its overall portfolio holdings.

Number of Shares
138,707
Previous 39,706 249.34%
Holding current value
$3.86 Million
Previous $879,000 243.57%
% of portfolio
0.23%
Previous 0.11%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 09, 2024

BUY
$18.84 - $24.94 $1.87 Million - $2.47 Million
99,001 Added 249.34%
138,707 $3.02 Million
Q1 2024

May 13, 2024

BUY
$18.06 - $25.3 $501,237 - $702,176
27,754 Added 232.21%
39,706 $879,000
Q4 2023

Jan 08, 2024

BUY
$12.19 - $22.43 $26,878 - $49,458
2,205 Added 22.62%
11,952 $257,000
Q3 2023

Oct 20, 2023

SELL
$13.28 - $20.3 $59,985 - $91,695
-4,517 Reduced 31.67%
9,747 $164,000
Q2 2023

Jul 11, 2023

BUY
$11.66 - $26.0 $166,318 - $370,864
14,264 New
14,264 $195,000

Others Institutions Holding CSTL

About CASTLE BIOSCIENCES INC


  • Ticker CSTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 26,297,000
  • Market Cap $733M
  • Description
  • Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...
More about CSTL
Track This Portfolio

Track Harbor Capital Advisors, Inc. Portfolio

Follow Harbor Capital Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Harbor Capital Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Harbor Capital Advisors, Inc. with notifications on news.